Roche subsidiary RoX Health invests six-figure sum in Viennese healthtech start-up XUND
XUND combines medical knowledge with proven algorithms to create high-quality solutions for the digital health market. With the strategic investment, RoX Health aims to accelerate XUND's growth into international markets and improve people's self-determined approach to health and illness with a digital health assistant for assessing disease symptoms and their risk.
The Viennese healthtech start-up XUND is in the final phase of its largest financing round to date and has also been able to win RoX Health, a subsidiary of Roche, one of the world's largest pharmaceutical companies, as a strategic investor. RoX Health, a company builder based in the start-up metropolis of Berlin, is participating in the start-up's current million-euro round with a six-figure sum.
The team of XUND, which now has more than 30 members, has developed a digital health assistant for symptom and risk assessment to help patients make informed decisions and navigate to the best place for treatment. The underlying technology is based on years of artificial intelligence (AI) research & development and is powered by automated analysis of millions of medical publications, case studies and patient records. Leading healthcare institutions such as Wiener Städtische, Generali and Semmelweis University Hospital already rely on the medically certified product of XUND, which can be directly integrated into the partners' digital ecosystem via API (Application Programming Interface). Now the step into the pharmaceutical sector follows: "We want to facilitate access to healthcare for as many people as possible. With RoX Health, we have found a strategic partner that opens up and accelerates our technology for use in promising areas such as digital therapeutics," says Tamás Petrovics, co-founder and CEO of XUND.
Roche's subsidiary RoX Health, launched in 2019, is pursuing a similar goal. Germany has established itself as a pioneer in the EU in terms of digital health applications (DiGA), a field in which RoX Health now also wants to make a contribution. With this cooperation, it is possible to integrate a certified solution as an important component in many future digital health applications, thus boosting networking in the healthcare system. "Our overall goal as a company builder, together with other relevant partners, is to help shape and drive the healthcare of tomorrow: towards a personalized, connected and digitalized healthcare ecosystem. We are convinced that intelligent digital healthcare solutions will play a central role within overall therapeutic concepts in the future," says Robert Schnitzler, Co-Founder and CEO of RoX Health and member of the Executive Committee of Roche Pharma AG.